Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Eur Child Adolesc Psychiatry ; 21(3): 141-7, 2012 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-22323074

RESUMO

Antibodies against glutamic acid decarboxylase 65 (GAD65) have been detected in the serum of patients with several neurological disorders. The presence of antibodies against GAD65 has not yet been examined in the serum of patients with neurodevelopmental disorders such as autism or attention-deficit/hyperactivity disorder (ADHD). In this study, GAD65 antibodies and total IgG were assayed in the serum of normal subjects and patients diagnosed with autism or ADHD. GAD65 antibodies were detected in the serum of 15% of children with autism (N = 20), 27% of children with ADHD (N = 15) and of none of the controls (N = 14). The serum of 60% of autistic and 53% of ADHD patients reacted with Purkinje neurons in mouse cerebellum. Serum from 20% of ADHD patients reacted also with the cells in the molecular and granule cell layers and cells in the vicinity of the Purkinje neurons. No association was found between the titer of GAD65 antibodies and total IgG levels, and presence of seizures or mental retardation. None of the ADHD patients were diagnosed with mental retardation. Serum anti-GAD65 antibodies may be a common marker of subgroups of patients with autism and ADHD. Reactions of serum antibodies with the cells in the cerebellum in these patients suggest direct effects on brain function. The subgroup of children with autism and ADHD that tests positive for GAD65 antibodies needs further characterization in a larger study.


Assuntos
Transtorno do Deficit de Atenção com Hiperatividade/imunologia , Transtorno Autístico/imunologia , Autoanticorpos/sangue , Glutamato Descarboxilase/imunologia , Animais , Transtorno do Deficit de Atenção com Hiperatividade/sangue , Transtorno Autístico/sangue , Autoanticorpos/imunologia , Cerebelo/citologia , Cerebelo/imunologia , Criança , Feminino , Humanos , Masculino , Camundongos , Neurônios/citologia , Neurônios/imunologia
2.
Curr Opin Ophthalmol ; 18(5): 392-7, 2007 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-17700232

RESUMO

PURPOSE OF REVIEW: Shaken baby syndrome is a common problem with a high morbidity and mortality. Ophthalmologists help manage this condition and therefore must keep abreast of current advances. RECENT FINDINGS: Clinical updates include the discovery that retinal folds and traumatic retinoschisis can very rarely occur after crush head injury, but remain specific for shaken baby syndrome in other scenarios. Pathology updates include new studies on orbital histology and woodpecker anatomy that suggest the retinal and optic nerve hemorrhages in shaken baby syndrome are caused by shaking itself rather than secondary to intracranial pathology. Regarding this shaking injury, some primary prevention strategies have proven surprisingly effective. In the near future, serum biomarkers may be used as a screening tool for inflicted neurotrauma. Animal models such as the neonatal pig and computer models using finite element analysis are promising experimental techniques for studying shaken baby syndrome. Finally, child abuse recently became an accredited subspecialty of pediatrics, which will lead to further advances in patient care, education, research and prevention. SUMMARY: Ophthalmologists play a key role in the diagnosis of shaken baby syndrome. In addition, they are in a unique position to study ophthalmic aspects of the syndrome, which in turn furthers the overall understanding of this devastating condition.


Assuntos
Traumatismos do Nervo Óptico/complicações , Hemorragia Retiniana/complicações , Síndrome do Bebê Sacudido/complicações , Pré-Escolar , Humanos , Lactente , Recém-Nascido , Oftalmologia/tendências , Traumatismos do Nervo Óptico/diagnóstico , Traumatismos do Nervo Óptico/prevenção & controle , Hemorragia Retiniana/diagnóstico , Hemorragia Retiniana/prevenção & controle , Síndrome do Bebê Sacudido/diagnóstico , Síndrome do Bebê Sacudido/prevenção & controle
3.
J AAPOS ; 7(2): 121-5, 2003 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-12736625

RESUMO

PURPOSE: Cryotherapy and indirect laser retinal photoablation are both effective in the treatment of retinopathy of prematurity (ROP). We describe the safety, efficiency, and effectiveness of combined cryotherapy and diode laser photocoagulation to treat threshold ROP. METHODS: Records of patients developing threshold ROP from January 1, 1996 through December 31, 1998, were retrospectively reviewed to identify those treated with combined cryotherapy and photocoagulation and followed up for at least 45 days postoperatively. Diode laser was used to ablate posterior avascular retina, and cryotherapy was used for anterior retina. Data reviewed included ocular and systemic complication rates, treatment duration, number of laser burns, most recent fundus examination, visual acuity, and refraction. RESULTS: In 13 patients, 23 eyes received combined treatment. No intraoperative complications occurred. Mean duration of anesthesia and treatment was 35 +/- 8 minutes/eye. A mean of 117 +/- 84 laser burns/eye were applied. In 20 of 23 eyes (87.0%), anatomic outcome was favorable at last examination. In 13 of 16 eyes (81.3%), functional (visual acuity) outcome was favorable (visual acuity better than 20/200) at 1 year. At 6 months or later, 14 of 16 eyes (87.5%) measured were myopic, of which 5 (31.3%) were highly myopic (> 6 diopters). CONCLUSIONS: The effectiveness of treating ROP with combined cryotherapy and diode laser photocoagulation compares with that of either modality alone. By decreasing the number of laser applications, combined therapy may be faster and technically easier for eyes with very posterior ROP. This may decrease the number of complications seen when either excessive cryotherapy or laser retinal photoablation is used.


Assuntos
Crioterapia , Fotocoagulação a Laser , Retinopatia da Prematuridade/terapia , Humanos , Lactente , Recém-Nascido , Miopia/etiologia , Miopia/fisiopatologia , Período Pós-Operatório , Retinopatia da Prematuridade/complicações , Retinopatia da Prematuridade/fisiopatologia , Estudos Retrospectivos , Índice de Gravidade de Doença , Resultado do Tratamento , Acuidade Visual
4.
J AAPOS ; 7(1): 69-70, 2003 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-12690374

RESUMO

Brimonidine is a selective alpha-2 adrenergic agonist used to treat glaucoma. There have been several reports of central nervous system depression after its use in infants. We observed rapid-onset bradycardia and decreased blood pressure in addition to central nervous system depression in 2 infants who received concomitant topical brimonidine and beta-blockers.


Assuntos
Agonistas alfa-Adrenérgicos/administração & dosagem , Agonistas alfa-Adrenérgicos/efeitos adversos , Antagonistas Adrenérgicos beta/administração & dosagem , Antagonistas Adrenérgicos beta/efeitos adversos , Bradicardia/induzido quimicamente , Glaucoma/tratamento farmacológico , Hipotensão/induzido quimicamente , Quinoxalinas/administração & dosagem , Quinoxalinas/efeitos adversos , Administração Tópica , Tartarato de Brimonidina , Feminino , Glaucoma/fisiopatologia , Humanos , Lactente , Recém-Nascido , Pressão Intraocular/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...